Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Astellas Pharma Inc's Subsidiary Receives Approval for Tacrolimus Extended Release Capsules from FDA
Astellas Pharma Inc announced that its United States-based subsidiary Astellas Pharma US, Inc. has received an approval from the U.S. Food and Drug Administration (FDA) for the new drug application of tacrolimus extended release capsules, which are used for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients.
Latest Developments for Astellas Pharma Inc
- Astellas Pharma Inc Looks to Sell Dermatology Assets-Reuters
- Astellas Pharma Inc Announces Approval of Prograf Capsules in Japan for Additional Indication of Interstitial Pneumonia Associated with Polymyositis /Dermatomyositis
- Astellas Pharma Inc to Establish Joint Venture with Amgen Inc.
- Astellas Pharma Inc Receives Marketing Authorization for VESOMNI from The Netherlands Medicines Evaluation Board
Latest Key Developments in Pharmaceuticals
- Alk Abello A/S Announces Positive Outcome of Pivotal Phase III Trial with Allergy Immunotherapy Tablet against House Dust Mite Allergy
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 Million-DJ
- Suheung Capsule Co Ltd to Merge with Subsidiary
- FDA Probes Deaths Of Two Patients On Eli Lilly And Co's Schizophrenia Drug-Reuters
- Share this
- Link this
- Digg this
Follow Reuters